{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:14:40Z","timestamp":1783977280668,"version":"3.55.0"},"reference-count":14,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Intravenous zoledronic acid is an established and generally well tolerated form of antiresorptive therapy for osteoporosis. Although mild arthralgias are a well-documented manifestation of the acute phase response to intravenous bisphosphonates, more severe musculoskeletal reactions manifesting as debilitating pain and joint effusions have been rarely documented in the current literature. In this case report, we discuss the case of a 55-year-old woman who developed severe painful bilateral knee effusions within 1 week of her first zoledronic acid infusion for osteoporosis. Prescribing physicians and patients should be made aware of this uncommon but important adverse effect to zoledronic acid.<\/jats:p>","DOI":"10.1210\/jcemcr\/luae199","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T15:41:27Z","timestamp":1729870887000},"source":"Crossref","is-referenced-by-count":1,"title":["Bilateral Knee Effusions Secondary to Zoledronic Acid Infusion"],"prefix":"10.1210","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0578-5460","authenticated-orcid":false,"given":"Jenny","family":"Wei","sequence":"first","affiliation":[{"name":"Rheumatology Department, Concord Repatriation General Hospital , Concord, NSW 2139 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Soo Ihn","family":"Cho","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Concord Repatriation General Hospital , Concord, NSW 2139 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"issue":"9","key":"2024110705253223200_luae199-B1","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2024110705253223200_luae199-B2","first-page":"499","article-title":"Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: a meta-analysis","volume":"32","author":"Peng","year":"2016","journal-title":"Pak J Med Sci"},{"issue":"17","key":"2024110705253223200_luae199-B3","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American society of clinical oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"2024110705253223200_luae199-B4","author":"Greear"},{"issue":"3","key":"2024110705253223200_luae199-B5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.rhu.0000221796.06383.4e","article-title":"Bisphosphonate-associated arthritis","volume":"12","author":"Diaz-Borjon","year":"2006","journal-title":"J Clin Rheumatol"},{"issue":"9","key":"2024110705253223200_luae199-B6","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00198-009-1123-7","article-title":"Flare-up of hand osteoarthritis caused by zoledronic acid infusion","volume":"21","author":"Werner de Castro","year":"2010","journal-title":"Osteoporosis int"},{"issue":"1","key":"2024110705253223200_luae199-B7","first-page":"69","article-title":"Severe polyarthritis secondary to zolendronic acid: a case report and literature review","volume":"12","author":"White","year":"2015","journal-title":"Clin Cases Miner Bone Metab"},{"key":"2024110705253223200_luae199-B8","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2025.08","article-title":"Osteoarthritis flare-up secondary to zoledronic acid infusion: case report","author":"Al Kiyumi","year":"2023","journal-title":"Oman Med J"},{"issue":"4","key":"2024110705253223200_luae199-B9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.cyto.2005.05.009","article-title":"Influence of bisphosphonates on the production of pro-inflammatory cytokines by activated human articular chondrocytes","volume":"31","author":"Van","year":"2005","journal-title":"Cytokine"},{"issue":"4","key":"2024110705253223200_luae199-B10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1078155207080806","article-title":"Significance and impact of bisphosphonate-induced acute phase responses","volume":"13","author":"Olson","year":"2007","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"2024110705253223200_luae199-B11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"2024110705253223200_luae199-B12","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","article-title":"OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis","volume":"27","author":"Bannuru","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"issue":"3","key":"2024110705253223200_luae199-B13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/imm.13283","article-title":"Zoledronate promotes inflammatory cytokine expression in human CD14-positive monocytes among peripheral mononuclear cells in the presence of \u03b3\u03b4 T cells","volume":"162","author":"Takimoto","year":"2020","journal-title":"Immunology"},{"key":"2024110705253223200_luae199-B14","first-page":"829","article-title":"Acute polyarthritis related to once-weekly alendronate in a woman with osteoporosis","volume":"31","author":"Gerster","year":"2004","journal-title":"J Rheumatol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/11\/luae199\/60396595\/luae199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/11\/luae199\/60396595\/luae199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T05:26:09Z","timestamp":1730957169000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luae199\/7841817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,10,18]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luae199","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,10,18]]},"article-number":"luae199"}}